Enveric Biosciences Inc.

1.20
-0.03 (-2.44%)
At close: Apr 17, 2025, 3:59 PM
1.22
1.75%
After-hours: Apr 17, 2025, 07:55 PM EDT
-2.44%
Bid 1.14
Market Cap 2.95M
Revenue (ttm) n/a
Net Income (ttm) -9.57M
EPS (ttm) -19.04
PE Ratio (ttm) -0.06
Forward PE -0.05
Analyst Buy
Ask 1.35
Volume 36,733
Avg. Volume (20D) 2,827,577
Open 1.20
Previous Close 1.23
Day's Range 1.14 - 1.22
52-Week Range 1.01 - 231.75
Beta 0.34

About ENVB

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosc...

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2015
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ENVB
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 736.82% from the latest price.

Stock Forecasts
1 month ago
+94.92%
Enveric Biosciences shares are trading higher afte... Unlock content with Pro Subscription
1 month ago
-13.87%
Enveric Biosciences shares are trading higher after the company announced its non-hallucinogenic psychedelic compounds showed promise for treating addiction and ADHD.